Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

Dimensional Fund Advisors LP lifted its position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 83.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 662,776 shares of the company's stock after purchasing an additional 302,087 shares during the quarter. Dimensional Fund Advisors LP owned 0.62% of Tango Therapeutics worth $2,048,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new position in Tango Therapeutics during the fourth quarter worth $33,000. Teacher Retirement System of Texas increased its position in shares of Tango Therapeutics by 35.8% during the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company's stock worth $45,000 after acquiring an additional 3,831 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Tango Therapeutics during the fourth quarter worth about $45,000. Renaissance Technologies LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter worth about $66,000. Finally, Wells Fargo & Company MN lifted its position in Tango Therapeutics by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 22,292 shares of the company's stock valued at $69,000 after acquiring an additional 7,599 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $13.00 price objective on shares of Tango Therapeutics in a report on Monday, April 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Tango Therapeutics has a consensus rating of "Buy" and a consensus target price of $12.33.

Tango Therapeutics Stock Down 8.2%

Tango Therapeutics stock opened at $1.29 on Thursday. Tango Therapeutics, Inc. has a 52 week low of $1.03 and a 52 week high of $12.02. The company's 50 day moving average price is $1.47 and its two-hundred day moving average price is $2.61. The stock has a market cap of $138.92 million, a P/E ratio of -1.09 and a beta of 1.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). The business had revenue of $5.39 million for the quarter, compared to the consensus estimate of $6.73 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. On average, equities analysts anticipate that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Want to see what other hedge funds are holding TNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.